AMRI acquired the outstanding equity interests of Aptuit’s Glasgow, U.K., business and has entered into a definitive agreement to acquire Aptuit's SSCI/West Lafayette, Indiana-based business. Both deals total $60 million. AMRI says the moves expand its drug product development and aseptic clinical manufacturing capabilities.

SSCI’s strengths lie in solving difficult drug substance and formulated drug product challenges, according to an AMRI official, who adds that SSCI is has expertise in solid-state chemistry and analytical services. In addition, Aptuit's Glasgow facility will extend AMRI's capabilities platform to include sterile injectable drug product formulation and clinical-stage manufacturing, noted William S. Marth, president and CEO of AMRI.

“The West Lafayette team brings extensive material science knowledge and technology and will expand our capabilities in analytical testing to include peptides, proteins, and oligonucleotides,” he said. “Aptuit's Glasgow operation strengthens our front end formulation expertise in our sterile injectable business, further extending our parenteral offerings and providing customers a single source to address their sterile fill/finish needs from formulation complete to commercial supply.”

The Glasgow business cost AMRI $24 million and the company will pay the remaining $36 million for the West Lafayette business.








This site uses Akismet to reduce spam. Learn how your comment data is processed.